EMA Application withdrawn: Radicava (edaravone) — Mitsubishi Tanabe Pharma GmbH

View source ↗

Summary

European Medicines Agency status update indicating withdrawal of the Radicava (edaravone) application by Mitsubishi Tanabe Pharma GmbH for amyotrophic lateral s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Radicava (edaravone)

Snippet

Status: Application withdrawn. Therapeutic area: Amyotrophic Lateral Sclerosis. MAH: Mitsubishi Tanabe Pharma GmbH. Orphan medicine